Large Inflow of Money Detected in Gilead Sciences

Gilead Sciences (GILD) : Thursdays money flow indicated an uptick to downtick ratio was at 1.11. The total value of inflow transactions on upticks was $103.59 million, whereas, the total value of outflow trades on downticks was $93.36 million. The total money flow was $10.23 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $5.88 million. The total value of the trades done on upticks was $8.96 million. Downticks saw transactions worth $3.08 million. The total uptick to downtick ratio stood at 2.91, mildly in favor of the bulls. Gilead Sciences (GILD) was trading with a -0.24% change over previous days close. It fell $0.21 during the day and reached $85.54. The stock was -1.17% compared to the previous weeks close.


The stock has recorded a 20-day Moving Average of 2.34% and the 50-Day Moving Average is 1.58%. Shares have dropped -26.51% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $120.37 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $84.51 and the 200 Day Moving Average price is recorded at $89.64.

Gilead Sciences (NASDAQ:GILD): The stock opened at $86.43 on Thursday but the bulls could not build on the opening and the stock topped out at $86.51 for the day. The stock traded down to $85.27 during the day, due to lack of any buying support eventually closed down at $85.54 with a loss of -0.24% for the day. The stock had closed at $85.75 on the previous day. The total traded volume was 8,104,351 shares.

In an insider trading activity,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 112,000 shares at $84.62 on July 5, 2016. The Insider selling transaction had a total value worth of $9,477,440. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.